![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Aim: To study the expression profile of SLC22A16 in gastric cancer (GC), its prognostic value and the potential mechanisms of its upregulation. Patients & methods: A retrospective study was performed by using data in the Human Protein Atlas and The Cancer Genome Atlas-Stomach Cancer (STAD). Results:SLC22A16 was significantly upregulated in GC tissues compared with normal stomach tissues. SLC22A16 upregulation independently predicted poor overall survival (hazard ratio [HR]: 1.424, 95% CI: 1.169–1.735; p < 0.001) and recurrence-free survival (HR: 1.658, 95% CI: 1.292–2.128; p < 0.001) in early GC and poor overall survival (HR: 1.411, 95% CI: 1.137–1.752; p = 0.002) in advanced GC. SLC22A16 DNA hypomethylation might be a compensation for DNA loss to maintain SLC22A16 elevation in GC. Conclusion:SLC22A16 might be a valuable prognostic marker in GC.
Keywords::
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.
Ethical conduct of research
The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.